Yaral To Expand Burgeoning Generics Portfolio With Support From Eversana
Industry Newcomer Poised For Three Additional Commercial Launches This Year
With three additional commercial launches lined up for 2023, Yaral has opted to expand its pre-existing partnership with life sciences service provider Eversana to support these activities.
You may also be interested in...
‘Leading’ Swiss Fertility Firm Launches US Authorized Generics Unit
With a mission to provide access “to high quality, affordable, authorized generics and complex generic medicines to enhance healthcare outcomes,” Yaral Pharma has launched in the US.
Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.
Fresenius Brings In Transparency Change For Kabi Unit
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.